An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
This trial found that 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6-months in terms of disease-free survival, with a better safety profile and lower costs.
1 Southampton University Hospital NHS Foundation Trust, Southampton, UK
2 Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
3 Department of Oncology, University of Oxford, Oxford, UK
4 The Christie Hospital NHS Foundation Trust, Manchester, UK
5 Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
6 Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark
7 Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
8 Australasian Gastro-Intestinal Trials Group, Camperdown, NSW, Australia
9 University of Uppsala, Uppsala, Sweden
10 Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK
11 Beatson West of Scotland Cancer Centre, Glasgow, UK
12 Royal United Hospital, Bath, UK
13 Addenbrooke’s Hospital, Cambridge, UK
14 Royal Cornwall Hospitals NHS Trust, Cornwall, UK
15 St Luke’s Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
16 Castle Hill Hospital, Hull, UK
17 Mount Vernon Cancer Centre, Northwood, UK
18 Bristol Cancer Institute, Bristol, UK
19 Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK
20 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
21 Barts Cancer Institute, Queen Mary University of London, London, UK
22 Department of Oncology, University College London, London, UK
23 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
24 Gloucestershire Oncology Centre, Cheltenham General Hospital, UK
25 Brighton and Sussex University Hospital Trust, Brighton, UK
26 Royal Marsden NHS Foundation Trust, London, UK
27 Poole Hospital NHS Foundation Trust, Poole, UK
28 Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK
29 North Wales Cancer Treatment Centre, Rhyl, UK
30 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
* Corresponding author Email: tim.iveson@uhs.nhs.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document